Screener
Aurinia Pharmaceuticals AUPH Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 177,398 | 170,256 |
| Commitments and contingencies (Note 5) | ||
| Shareholders' equity | ||
| Common shares — no par value, Unlimited shares authorized, 132,907 and 132,323 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1,117,248 | 1,120,035 |
| Additional paid-in capital | 76,192 | 111,263 |
| Accumulated other comprehensive loss | (977) | (599) |
| Accumulated deficit | (577,599) | (649,368) |
| Total shareholders' equity | 614,864 | 581,331 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's common stock, par value (in dollars per share)?
- Aurinia Pharmaceuticals (AUPH) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
- What does common stock, par value (in dollars per share) mean?
- Common stock, par value (in dollars per share)
Ask your AI about Aurinia Pharmaceuticals's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude